NASDAQ · PBYI
Puma Biotechnology Inc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PBYI: Nov 05, 2026
Puma Biotechnology Inc Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.06. The reported EPS for the same quarter last year was $0.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.06 | $0.06 | $0.06 | 1 |
| Dec 2026 | $0.23 | $0.23 | $0.23 | 1 |
| Mar 2027 | $0.04 | $0.04 | $0.04 | 1 |
| Jun 2027 | $0.07 | $0.07 | $0.07 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Oct 20, 8:40 AM EDTWill Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
- Zacks · Oct 19, 8:00 AM EDTThe Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyAstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.
- Zacks · Oct 16, 8:45 AM EDT4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthAZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
- RTTNews · Oct 12, 5:40 AM EDTBiotech Stocks At 52-Week Highs – HUM +11%, MRNA +14%, PBYI, ABBV, RCEL(RTTNews) – The following biotech stocks reached a 52-week high on October 9, 2026, driven by catalysts such as achieving new regulatory milestones.
- RTTNews · Oct 1, 5:04 AM EDTBiotech Stocks At 52-Week Highs – PGEN, EXEL, TWST, HNGE, PBYI(RTTNews) – The following biotech stocks reached a 52-week high on September 30, 2026, driven by key catalysts such as promising results from clinical trials.
- Zacks · Sep 18, 10:48 AM EDTPBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer BeginsPuma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
- Zacks · Sep 9, 11:30 AM EDTAxsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- The Motley Fool · Aug 14, 10:27 AM EDTPuma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 12, 9:40 AM EDTIs Puma Biotechnology (PBYI) a Great Value Stock Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks · Aug 7, 11:15 AM EDTPBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance RaisedPuma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
- MarketBeat · Aug 7, 3:04 AM EDTPuma Biotechnology Q2 Earnings Call Highlights3 small-cap biotechs with potential breakthroughs in 2024Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net inco
- Zacks · Aug 6, 7:10 PM EDTPuma Biotech (PBYI) Q2 Earnings and Revenues Top EstimatesPuma Biotech (PBYI) delivered earnings and revenue surprises of +90.00% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Puma Biotechnology Inc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.